Welcome to our dedicated page for Grail SEC filings (Ticker: GRAL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Biotech disclosures can feel like a second language—especially when GRAIL’s 10-K spells out hundreds of pages of clinical trial statistics, cash-burn tables, and regulatory risk factors tied to its Galleri multi-cancer early detection test. Finding the pivotal trial read-outs or decoding executive stock moves before major data releases shouldn’t require a medical degree.
Stock Titan’s platform turns that challenge into a two-minute task. Our AI-powered summaries convert dense narratives into plain English, so understanding GRAIL SEC documents with AI is as direct as reading a headline. Receive real-time alerts the moment a GRAIL Form 4 insider transactions real-time notice hits EDGAR, review a distilled GRAIL quarterly earnings report 10-Q filing, or open a GRAIL 8-K material events explained brief that pinpoints new clinical milestones.
Use the filings that matter most:
- GRAIL annual report 10-K simplified – track R&D outlays, patent positions, and Galleri commercialization strategy.
- 10-Q trends – rapid GRAIL earnings report filing analysis for cash-runway checks.
- GRAIL insider trading Form 4 transactions – uncover buying or selling before clinical data drops.
- GRAIL proxy statement executive compensation – see how trial success metrics drive pay packages.
Whether you’re monitoring GRAIL executive stock transactions Form 4 or verifying a new partnership disclosed in an 8-K, our comprehensive, continuously updated library ensures GRAIL SEC filings explained simply. Skip the jargon, focus on the insight, and make faster, better-informed decisions about this precision-oncology pioneer.
GRAIL, Inc. (GRAL) reported Q2 2025 results showing revenue growth and materially smaller operating losses versus prior-year periods after large pushdown impairments in 2024. Total revenue was $35.5 million for the quarter and $67.4 million for the six months, driven mainly by screening revenue. Net loss was $114.0 million for the quarter and $220.2 million for six months, versus multi‑hundred‑million and billion‑level losses in 2024 primarily from goodwill and IPR&D impairments. The balance sheet shows $130.8 million of cash and restricted cash and $475.3 million of short‑term marketable securities; management believes these resources are sufficient to fund operations for at least 12 months. The company completed its Spin‑Off from Illumina, received $932.3 million of disposal funding subject to a time‑limited clawback, and disclosed positive registrational trial signals (NHS‑Galleri prevalent round and initial PATHFINDER 2 top‑line results). Significant amortization and prior impairment charges continue to affect reported operating results and accumulated deficit.
GRAIL, Inc. furnished a press release reporting its financial results for the second quarter ended June 30, 2025; the press release is attached as Exhibit 99.1 to this current report. The 8-K text states the press release announces second-quarter financial results but does not include the underlying financial tables or metrics within the filing itself.
The exhibit is furnished, not filed, so the press release is not automatically incorporated by reference into other SEC filings unless explicitly stated. The report also identifies the company as an emerging growth company and confirms its common stock (par value $0.001) trades under the symbol GRAL on the Nasdaq Global Select Market. Readers must consult Exhibit 99.1 for the full financial figures and management commentary.
FAQ
What is the current stock price of Grail (GRAL)?
What is the market cap of Grail (GRAL)?
